July 31, 2018
SciBac has been awarded up to $3.76 million in non-dilutive funding by CARB-X, a public-private partnership devoted to accelerating early medical R&D to combat the rising threat of antibiotic resistant Superbugs. This award supports development of SciBac’s novel biotherapeutic to treat and prevent Clostridium difficile infections (CDI).
January 28, 2018
Learn all about CEO Jeanette Mucha, the story of how SciBac was founded, MERGE technology, and the biotherapeutic pipeline that harnesses the microbiome to tackle antibiotic resistant diseases.
January 27, 2018
SciBac to present at 11:15 am, March 30 2018 at UCLA California Nanosystems Institute, Los Angeles, CA.
January 1, 2018
SciBac CEO, Jeanette Mucha, to present at the Biotech Showcase™ Annual Conference on January 10, 2018, 1:45pm at Hilton Union Square, Room Franciscan - A.
September 19, 2017
U.S. patent just issued for SciBac's "Method for Producing Chimeric Microbial Hybrids."
July 18, 2017
SciBac will use its MERGE technology platform to develop non-GMO hybrid microorganisms for the purpose of creating a cost-efficient expression of enzymes for Novozymes.
May 3, 2017
Empowering the Cutting-Edge Companies of Tomorrow, Today SciBac announced as a finalist, having been judged by experts with entrepreneurial, investment, start-up, economic development, capital formation, and academic backgrounds from both the public and private sectors.
Apr 13, 2017
Jeanette Mucha, CEO of SciBac, said: “The Breakout Labs grant will allow us to further advance our C. diff program, developing a live biotherapeutic that can destroy the harmful C. diff pathogen without antibiotics, while nurturing a healthy gut microbiome.”